Last reviewed · How we verify

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile

Sanofi · Phase 3 active Small molecule

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile is a anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.

Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Ciclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage. Methotrexate is an antifolate that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation. Fluorouracile is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair.

Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Ciclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage. Methotrexate is an antifolate that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation. Fluorouracile is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.

At a glance

Generic nameepidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
SponsorSanofi
Drug classanthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor
Targettopoisomerase II, microtubules, dihydrofolate reductase, thymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Epidoxorubicine's mechanism of action involves the intercalation of DNA strands, which inhibits the progression of topoisomerase II and induces apoptosis in cancer cells. Docetaxel's mechanism of action involves the stabilization of microtubules, preventing cell division and leading to cell death. Ciclophosphamide's mechanism of action involves the addition of an alkyl group to DNA, causing cross-linking and DNA damage. Methotrexate's mechanism of action involves the inhibition of dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation. Fluorouracile's mechanism of action involves the inhibition of thymidylate synthase, disrupting DNA synthesis and repair.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile

What is epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile is a anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor drug developed by Sanofi, indicated for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.

How does epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile work?

Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Ciclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage. Methotrexate is an antifolate that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation. Fluorouracile is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair.

What is epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile used for?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile is indicated for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer, Metastatic pancreatic cancer.

Who makes epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile in?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile belongs to the anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor class. See all anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor drugs at /class/anthracycline-antibiotic-taxane-alkylating-agent-antifolate-thymidylate-synthase-inhibitor.

What development phase is epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile in?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile is in Phase 3.

What are the side effects of epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile?

Common side effects of epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Diarrhea, Fatigue.

What does epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile target?

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile targets topoisomerase II, microtubules, dihydrofolate reductase, thymidylate synthase and is a anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor.

Related